EWAF
TEAS WITHDRAWAL OF ATTORNEY RECEIVED-FIRM RETAINS
07/06/2026
Back to search
Official data from USPTO
ALLERGAN
Did you know this trademark is already registered in United States?
Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.
Active USPTO registrationType: CombinedOffice: US
Risk and opportunity diagnosis
Executive reading for naming, filing, and monitoring decisions.
USPTO status
Active USPTO registration
Case type
Application and registration
Recorded events
65
Latest update
07/09/2026
Classification
Registered
Trademark type
Combined
Nice classes
5, 10
Filing date
06/12/2015
Registration date
04/10/2018
Expiration date
-
Recommended action
Perform a full collision analysis and validate classes before any filing or trademark investment.
Next step
These are the details of the registration process. Even so, constant monitoring is what ensures peace of mind that your main asset remains protected.
Complete case details
Structured fields from the responsible authority and the official record.
Status date
08/20/2024
Last transaction
07/09/2026
Responsible office
United States Patent and Trademark Office
Status code
702
Official register
Principal Register
Filing basis
Intent to use
First use anywhere
06/30/2017
First use in commerce
06/30/2017
Drawing code
3
Owner type
03
Owner location
North Chicago, IL, US
Examiner
MARESCA, MEREDITH Z
Current location
Historical data usage
Mark description
The mark consists of the word "ALLERGAN" in a stylized dark blue font to the left of which is a stylized futuristic comet design comprised of circles that are as follows moving from right to left: three large dark blue circles, followed next by four medium blue circles that are large on the outside with the two middle circles being smaller, followed next by three small light blue circles, followed next by three large green circles, followed next by three smaller medium green circles, followed next by three small yellow circles, with the last circle being the point of the comet.
Holders and representatives
Holders
Allergan, Inc.
Allergan, Inc.
Representatives
Matthew O. Brady AbbVie Inc.
Technical classification
Nice Classes
Class 5Class 10
Vienna Codes
No Vienna codes available.
Goods and services
Class 5
House mark used for a line of pharmaceuticals used in connection with anti-agingthe treatment of glabellar linesfacial wrinklesasymmetries and defects and conditions of the human skinfacial aesthetic surgeryfacial aesthetic reconstructionbreast aesthetics; topical antibioticsanti-inflammatoryanti-infectiveanti-glaucoma and decongestant formulationspharmaceutical preparations to treat and prevent glaucoma; ocular wetting solutionseye dropsartificial tears and gels for the treatment of minor ocular inflammations and allergic conditions; Pharmaceutical preparations for the treatment of neurological disordersmuscle dystoniassmooth muscle disordersautonomic nerve disordersheadacheshyperhydrosissports injuriescerebral palsyspasmstremors and pain; dermatological formulationsmedicated dry skin lotions and creamsacne medications and medicated skin lighteners; Oraltransdermalinjectable and intravaginal contraceptive preparations; intravaginal contraceptive sponge; Hormone replacement therapy preparations; Pharmaceutical preparations for the prevention of preterm birth or pregnancy; Pharmaceutical preparations for the treatment and prevention of urinary incontinence and overactive bladder; Pharmaceutical preparations for the treatment and prevention of iron deficiency and anemia; Pharmaceutical preparations for the treatment and prevention of osteoporosis; Pharmaceutical preparations for the treatment and prevention of endometriosis; Pharmaceutical preparations for the treatment and prevention of symptoms associated with uterine fibroids; Iron chelating pharmaceutical preparations; Fertility enhancing preparations; Pharmaceuticals and medicines for the treatment and prevention of sexual dysfunction; Pharmaceuticals and medicines for the prevention and treatment of conditions affecting sensory organs; Pharmaceuticals and medicines for the prevention and treatment of conditions affecting the central nervous system; Pharmaceuticals and medicines for the prevention and treatment of conditions affecting urogenital organs; Pharmaceuticals and medicines for the prevention and treatment of conditions affecting circulatory systems; Pharmaceuticals and medicines for the treatment of cardiovascular disease and blood pressure; Pharmaceutical preparations for the treatment and prevention of digestive tractgastrointestinal and dermatological diseases and disorders; Pharmaceuticals and medicines for the treatment and prevention of irritable bowel syndrome; Pharmaceutical preparations that supportencourage or promote bone strength or bone health or which are used in the treatment of bone disorders or bone diseases; Antibiotics; Antifungal preparations; Antivirals and Antiprotozoals; Pharmaceutical preparations for the prevention and treatment of bacterial infections; Pharmaceutical preparations for the prevention and treatment of diabetes and diabetic neuropathy; Pharmaceutical preparations for the prevention and treatment of pain and neuropathic pain; Pharmaceutical preparations for the prevention and treatment of respiratory system diseases and disorders; Pharmaceutical preparations for the prevention and treatment of neurological diseases and disorders; Pharmaceutical preparations for the prevention and treatment of neurodegenerative diseases and disorders; Pharmaceutical preparations for the prevention and treatment of peripheral nervous system diseases and disorders; Pharmaceutical preparations for the prevention and treatment of hypertension; Pharmaceutical preparations for the prevention and treatment of Alzheimer's diseasedementiaAIDS-related dementiacentral nervous system disordersneurological disordersneurodegenerative disordersdepressionneuroprotective agent; antidepressants; pharmaceuticalsantipsychotics; coronary vasodilating agents; Pharmaceutical preparations for the treatment of hypothyroidism; Pharmaceuticals and cosmeceuticalsmedicated skin cleanserstonersmoisturizersrejuvenatorsrehydrating creamslotions for the face and body; medicated cosmetic skin care preparations
Class 10
House mark used for a line of surgicalmedicaldental and veterinary apparatus and instrumentsdiagnostic test kits principally composed of medical diagnostic meters that measure conditions of the cardio-vascular and immune systems; intra-uterine non-chemical contraceptive devices; medical diagnostic instruments for the analysis of body fluids; medical devices for treating glabellar linesfacial wrinklesasymmetries and defects and conditions of the human skinfor use in facial aesthetic surgeryfacial aesthetic reconstructionbreast aesthetics and ophthalmic related diseases and disorders
Publications
History of USPTO decisions and trademark events.
65 publications found
TCCA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
07/06/2026
ARAA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
07/06/2026
REAP
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
07/06/2026
NA85
NOTICE OF ACCEPTANCE OF SEC. 8 & 15 - E-MAILED
08/20/2024
C15A
REGISTERED - SEC. 8 (6-YR) ACCEPTED & SEC. 15 ACK.
08/20/2024
APRE
CASE ASSIGNED TO POST REGISTRATION PARALEGAL
08/20/2024
E815
TEAS SECTION 8 & 15 RECEIVED
02/05/2024
CHAN
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
04/10/2023
TCCA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
04/10/2023
ARAA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
04/10/2023
REAP
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
04/10/2023
COAR
TEAS CHANGE OF OWNER ADDRESS RECEIVED
04/10/2023
REM1
COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED
04/10/2023
R.PR
REGISTERED-PRINCIPAL REGISTER
04/10/2018
SUNA
NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED
03/03/2018
CNPR
ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED
03/02/2018
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
02/09/2018
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
02/09/2018
ERFR
TEAS REQUEST FOR RECONSIDERATION RECEIVED
02/08/2018
GNFN
NOTIFICATION OF FINAL REFUSAL EMAILED
10/27/2017
GNFR
FINAL REFUSAL E-MAILED
10/27/2017
CNFR
SU - FINAL REFUSAL - WRITTEN
10/27/2017
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
10/25/2017
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
10/25/2017
ALIE
ASSIGNED TO LIE
10/24/2017
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
10/10/2017
GNRN
NOTIFICATION OF NON-FINAL ACTION E-MAILED
10/04/2017
GNRT
NON-FINAL ACTION E-MAILED
10/04/2017
CNRT
SU - NON-FINAL ACTION - WRITTEN
10/04/2017
MDSC
NOTICE OF DESIGN SEARCH CODE E-MAILED
09/29/2017
SUPC
STATEMENT OF USE PROCESSING COMPLETE
09/28/2017
DPCC
DIVISIONAL PROCESSING COMPLETE
09/28/2017
AITU
CASE ASSIGNED TO INTENT TO USE PARALEGAL
09/28/2017
IUAF
USE AMENDMENT FILED
09/20/2017
DRRR
DIVISIONAL REQUEST RECEIVED
09/20/2017
ERTD
TEAS REQUEST TO DIVIDE RECEIVED
09/20/2017
EISU
TEAS STATEMENT OF USE RECEIVED
09/20/2017
EXRA
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
03/28/2017
EX2G
SOU EXTENSION 2 GRANTED
03/24/2017
EXT2
SOU EXTENSION 2 FILED
03/24/2017
EEXT
SOU TEAS EXTENSION RECEIVED
03/24/2017
EXRA
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
09/16/2016
EX1G
SOU EXTENSION 1 GRANTED
09/14/2016
EXT1
SOU EXTENSION 1 FILED
09/14/2016
EEXT
SOU TEAS EXTENSION RECEIVED
09/14/2016
NOAM
NOA E-MAILED - SOU REQUIRED FROM APPLICANT
04/26/2016
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
03/01/2016
PUBO
PUBLISHED FOR OPPOSITION
03/01/2016
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
02/10/2016
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
01/22/2016
XAEC
EXAMINER'S AMENDMENT ENTERED
01/22/2016
GNEN
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
01/22/2016
GNEA
EXAMINERS AMENDMENT E-MAILED
01/22/2016
CNEA
EXAMINERS AMENDMENT -WRITTEN
01/22/2016
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
01/20/2016
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
01/19/2016
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
01/19/2016
GPRN
NOTIFICATION OF PRIORITY ACTION E-MAILED
09/22/2015
GPRA
PRIORITY ACTION E-MAILED
09/22/2015
CPRA
PRIORITY ACTION WRITTEN
09/22/2015
DOCK
ASSIGNED TO EXAMINER
09/22/2015
MDSC
NOTICE OF DESIGN SEARCH CODE E-MAILED
06/18/2015
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
06/17/2015
NWAP
NEW APPLICATION ENTERED
06/16/2015
Continuous trademark protection
Get notified about every new filing that threatens ALLERGAN or your mark.
Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.